Refine
Language
- English (13)
Is part of the Bibliography
- yes (13)
Keywords
- Epigenetics (2)
- endothelin-converting enzyme (2)
- insulin resistance (2)
- neutral endopeptidase (2)
- pregnancy (2)
- ACE I/D polymorphism (1)
- Cardiac ischemia/reperfusion (1)
- Chronic kidney disease (1)
- Dipeptidylpeptidase-4 (1)
- Endothelial nitric oxide synthase (1)
- Endothelin (1)
- Fetal programming (1)
- GLUT1 XbaI gene polymorphism (1)
- Gestational diabetes (1)
- Global DNA methylation (1)
- Hypermethylation (1)
- Infarct size (1)
- Insulin resistance (1)
- LC-MS/MS (1)
- Mice (1)
- Myocardial ischemia (1)
- Nitric oxide (1)
- Placenta (1)
- Rats (1)
- Renal failure (1)
- Renin-angiotensin-aldosterone system (1)
- Stromal cell-derived factor-1 (1)
- TGF-beta 1 (1)
- birthweight (1)
- cardiac remodeling (1)
- disproportional intrauterine growth retardation (1)
- distal convoluted tubule (1)
- eNOS (1)
- fasting blood glucose (1)
- fatty liver (1)
- fetal programming (1)
- fetal sex (1)
- glycemic control (1)
- glycemic control during pregnancy (1)
- kidney (1)
- low birth weight (1)
- metabolism (1)
- pregnancy induced diabetes (1)
- renovascular hypertension (1)
- total glycated hemoglobin (1)
- total glycosylated hemoglobin (1)
- transient receptor potential (1)
- ultrasound (1)
- vesicular trafficking (1)
Institute
Hypomagnesemia affects insulin resistance and is a risk factor for diabetes mellitus type 2 (DM2) and gestational diabetes mellitus (GDM). Two single nucleotide polymorphisms (SNPs) in the epithelial magnesium channel TRPM6 ((VI)-I-1393, (KE)-E-1584) were predicted to confer susceptibility for DM2. Here, we show using patch clamp analysis and total internal reflection fluorescence microscopy, that insulin stimulates TRPM6 activity via a phosphoinositide 3-kinase and Rac1-mediated elevation of cell surface expression of TRPM6. Interestingly, insulin failed to activate the genetic variants TRPM6 ((VI)-I-1393) and TRPM6((KE)-E-1584), which is likely due to the inability of the insulin signaling pathway to phosphorylate TRPM6(T-1391) and TRPM6(S-1583). Moreover, by measuring total glycosylated hemoglobin (TGH) in 997 pregnant women as a measure of glucose control, we demonstrate that TRPM6((VI)-I-1393) and TRPM6((KE)-E-1584) are associated with higher TGH and confer a higher likelihood of developing GDM. The impaired response of TRPM6((VI)-I-1393) and TRPM6((KE)-E-1584) to insulin represents a unique molecular pathway leading to GDM where the defect is located in TRPM6.
Birth weight within the normal range is associated with a variety of adult-onset diseases, but the mechanisms behind these associations are poorly understood(1). Previous genome-wide association studies of birth weight identified a variant in the ADCY5 gene associated both with birth weight and type 2 diabetes and a second variant, near CCNL1, with no obvious link to adult traits(2). In an expanded genome-wide association metaanalysis and follow-up study of birth weight (of up to 69,308 individuals of European descent from 43 studies), we have now extended the number of loci associated at genome-wide significance to 7, accounting for a similar proportion of variance as maternal smoking. Five of the loci are known to be associated with other phenotypes: ADCY5 and CDKAL1 with type 2 diabetes, ADRB1 with adult blood pressure and HMGA2 and LCORL with adult height. Our findings highlight genetic links between fetal growth and postnatal growth and metabolism.
Background: Dipeptidylpeptidase-4 inhibition is reported to have beneficial effects on myocardial ischemia. Mechanisms might include a reduced degradation of stromal cell-derived factor-1 alpha with subsequent increased recruitment of circulating stem cells and/or incretin receptor-dependent pathways. This study evaluated the novel xanthine-based dipeptidylpeptidase-4 inhibitors linagliptin (BI 1356) and BI 14361 in cardiac ischemia.
Methods: Male Wistar rats were pretreated with linagliptin or BI 14361 and subjected to ligation of the left anterior descending coronary artery for 30 min.
Results: Dipeptidylpeptidase-4 inhibition significantly reduced the infarct size after 7 days (-27.7%, p<0.05) and 8 weeks (-18.0%, p<0.05). There was a significantly improved maximum rate of left ventricular pressure decline (dP/dt min) in linagliptin-treated animals 8 weeks after ischemia/reperfusion. Apart from that, treatment did not improve cardiac function as determined by echocardiography and cardiac catheterization. Immunohistological staining revealed an increased number of cells positive for stromal cell-derived factor-1 alpha, CXCR-4 and CD34 within and around the infarcted area of BI 14361-treated animals.
Conclusions: Linagliptin and BI 14361 are able to reduce infarct size after myocardial ischemia. The immunohistological findings support the hypothesis that dipeptidylpeptidase-4 inhibition via reduced cleavage of stromal cell-derived factor-1 alpha might lead to an enhanced recruitment of CXCR-4+ circulating progenitor cells.